NCT02693080View on ClinicalTrials.gov

CT Perfusion Imaging in Predicting Treatment Response in Patients With Non-small Cell Lung Cancer or Lung Metastases Treated With Stereotactic Ablative Radiation Therapy

PHASE1CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

January 19, 2016

Primary Completion Date

April 29, 2020

Study Completion Date

April 29, 2020

Conditions
Malignant Lung NeoplasmMetastatic Malignant Neoplasm in the LungNon-Small Cell Lung CarcinomaStage IV Lung Cancer
Interventions
DEVICE

CAPP-Seq

Cancer Personalized Profiling by Deep Sequencing (CAPP-Seq) is an assay which allows quantitative assessment of the levels of circulating-tumor DNA in the blood sample.

DRUG

Isovue-200

Contrast agent

RADIATION

Computed Tomography Perfusion Imaging

Trial Locations (1)

94304

Stanford University, School of Medicine, Palo Alto

All Listed Sponsors
lead

Stanford University

OTHER

NCT02693080 - CT Perfusion Imaging in Predicting Treatment Response in Patients With Non-small Cell Lung Cancer or Lung Metastases Treated With Stereotactic Ablative Radiation Therapy | Biotech Hunter | Biotech Hunter